The results of the univariate survival analysis performed using a Kaplan–Meier curve revealed a shorter overall survival in BC patients with the TZAP mutation (52.8 vs. 87.3 months, χ2 = 4.37, p = 0.037; Figure 2A). Here, ZBTB48 is linked to breast cancer.